Royalty Pharma (RPRX) investor relations material

Executive summary

• Achieved 13% growth in Royalty Receipts to $887 million and 10% growth in Portfolio Receipts to $925 million in Q1 2026, driven by a diversified portfolio and strong business momentum.

• Net income attributable to shareholders increased 23.1% to $295 million, with diluted EPS of $0.67, up from $0.55 in Q1 2025.

• Expanded leadership and capabilities, including new hires to strengthen Asia-Pacific and AI initiatives, and advanced multiple R&D co-funding agreements.

• Announced up to $1.25 billion in new royalty transactions, including R&D co-funding deals with Johnson & Johnson and Teva.

• Raised full-year 2026 Portfolio Receipts guidance to $3,325–$3,450 million, reflecting expected Royalty Receipts growth of 4–8%.

Financial highlights

• Royalty Receipts grew 13% year-over-year to $887 million; Portfolio Receipts up 10% to $925 million in Q1 2026.

• Adjusted EBITDA rose 21% to $889 million; Portfolio Cash Flow increased 18% to $722 million, representing 78% of Portfolio Receipts.

• Net margin remained high at around 78%, reflecting strong cash conversion.

• Weighted average diluted shares outstanding declined 4% to 557 million due to share buybacks.

• Cash and cash equivalents at quarter-end: $586 million; total debt: $9.2 billion.

Outlook and guidance

• 2026 Portfolio Receipts guidance raised to $3,325–$3,450 million, up from prior $3,275–$3,425 million; Royalty Receipts growth expected at 4–8%.

• Q2 2026 Portfolio Receipts expected between $740–$760 million due to royalty rate resets.

• Operating and professional costs projected at 5.5–6.5% of Portfolio Receipts; interest paid expected at $350–$360 million for 2026.

• Guidance assumes no major unforeseen adverse events or FX changes.

• Milestones and other contractual receipts projected to decrease from $128 million in 2025 to $60 million in 2026.